-
Signature
-
/s/ Jason Cavalier, Attorney-in-Fact for Maria Palasis, Ph.D.
-
Issuer symbol
-
LYRA
-
Transactions as of
-
06 Jan 2026
-
Net transactions value
-
-$5,726
-
Form type
-
4
-
Filing time
-
08 Jan 2026, 16:30:11 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Palasis Maria |
President & CEO, Director |
C/O LYRA THERAPEUTICS, INC., 480 ARSENAL WAY, WATERTOWN |
/s/ Jason Cavalier, Attorney-in-Fact for Maria Palasis, Ph.D. |
08 Jan 2026 |
0001810701 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
LYRA |
Common Stock |
Sale |
$5,726 |
-1,702 |
-0.15% |
$3.36 |
1,096,733 |
06 Jan 2026 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: